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Abstract
The steroidogenic pathway within the ovary gives rise to progestins, androgens and oestrogens, all
of which act via specific nuclear receptors to regulate reproductive function and maintain fertility.
The role of progestins in follicular growth and development is limited, its action confined largely to
ovulation, although direct effects on granulosa cell function have been reported. Consistent with
these findings, progesterone receptor knockout mice are infertile because they cannot ovulate.
Androgens have been shown to promote early follicular growth, but also to impede follicular
development by stimulating atresia and apoptosis. The inability of androgens to transduce a signal
in mice lacking androgen receptors culminates in reduced fertility. Oestrogens are known to exert
effects on granulosa cell growth and differentiation in association with gonadotrophins. Studies with
oestrogen receptor knockouts and oestrogen depleted mice have shown us that oestrogen is
essential for folliculogenesis beyond the antral stage and is necessary to maintain the female
phenotype of ovarian somatic cells. In summary, the action of steroids within the ovary is based on
the developmental status of the follicle. In the absence of any single sex steroid, ovarian function
and subsequently fertility, are compromised.
Introduction
Follicular development begins during foetal life with the
transformation of primordial germ cells into oocytes and
their enclosure in structures called follicles. In most mam-
mals, primordial follicles form either before, or in the first
few days after birth. Primordial follicles give rise to pri-
mary follicles which transform into preantral (secondary
follicles) then antral follicles (tertiary follicles) and finally
preovulatory, Graafian follicles, in a co-ordinated series of
transitions regulated by hormones and local intraovarian
factors. The growth and differentiation of follicles from
the primordial population is termed folliculogenesis.
With the LH surge, Graafian follicles rupture and oocytes
are released, leaving the follicular cells to luteinise and
form a corpus luteum.
Sex steroids play important roles in the growth and differ-
entiation of reproductive tissues and in the maintenance
of fertility. Produced de novo from cholesterol, progestins,
androgens and oestrogens are synthesised by the ovary in
a sequential manner, with each serving as substrate for the
subsequent steroid in the pathway. The two-cell, two-
gonadotrophin model describes the role of theca and
granulosa cells in the production of steroids, highlighting
the cooperation between the two cell types, which is nec-
essary for oestrogen production (Figure 1). Given that sig-
nal transduction for these hormones usually requires the
binding and activation of a ligand-specific receptor, one
cannot easily dissociate these components and assign
definitive roles. The steroid hormones signal via nuclear
receptors to regulate transcriptional events. These recep-
tors form part of a nuclear receptor superfamily, all of
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which contain common structural elements [1,2]. These
include a highly conserved DNA binding domain (DBD),
a moderately conserved ligand binding domain (LBD)
and 2 transactivation domains, AF1 located in domain A/
B and AF2 in domain E/F (Figure 2). This review will
address the roles that steroid hormones play in follicular
development. It will encompass the direct actions of ster-
oids in the ovary that have been reported and include a
discussion of relevant models of ovarian dysfunction and
nuclear receptor knockout mouse models that lead to dis-
ruption of steroid hormone signalling mechanisms and
thus an inability of steroids to fulfil their regulatory roles.
Progestins
In the female reproductive tract, progesterone plays key
roles in ovulation, implantation and the maintenance of
pregnancy [3]. This review is confined to the roles proges-
terone plays in regulating granulosa cell function and fol-
licle rupture during ovulation.
Progesterone receptors (PR) comprise two forms PR-A and
PR-B [4,5], although they arise from a single gene. These
receptors appear to have functionally different roles [6,7]
and in vitro data suggests that PR-A is a dominant repres-
sor of PR-B [8,9], with the balance of the two forms deter-
mining cellular responsiveness. PR-A and PR-B exhibit
different transactivation properties which are cell and pro-
moter specific [5,9-11], indicating actions on separate
groups of genes for each receptor, in response to proges-
terone. They also respond differently to progestin antago-
nists with PR-B, but not PR-A, becoming a transcriptional
activator on binding antiprogestin [12].
PR protein has been localised immunohistochemically to
theca of small antral follicles and granulosa cells of preo-
vulatory follicles that had been exposed to LH/hCG, or
were undergoing luteinisation, in primate and rabbit ova-
ries [13,14]. PR mRNA has been localised in immature rat
ovaries to granulosa cells of large follicles following
PMSG/hCG treatment and to large follicles of adult rat
ovaries that had been exposed to the LH surge [15]. When
the LH surge was blocked, PR mRNA was not induced.
Similarly, LH induced PR mRNA expression by cultured
porcine granulosa cells [16]. In cultured rat granulosa
cells, PR mRNA was induced by LH in a dose and time
dependent manner, with the shorter form, PR-A more
abundant than the long form, PR-B [17]. The Antipro-
gestins RU486 and ZK98299, blocked LH-stimulated
luteinisation of granulosa cells isolated from preovulatory
follicles [17]. PR mRNA was also expressed by primate
granulosa cells following an ovulatory dose of hCG, with
whole ovaries and corpora lutea also expressing PR [18].
These findings promote the hypothesis that LH-induced
PR is essential for ovulation and luteinisation.
Progestins have been shown to enhance the activity of
steroidogenic enzymes in gonadotrophin primed granu-
losa cells [19] and to enhance progesterone production by
these cells [20]. Consistent with this finding, RU486
inhibited progesterone production by cultured human
granulosa cells by way of decreasing the activity of 3β
hydroxysteroid dehydrogenase [21]. The direct actions of
progesterone on granulosa cells extend to: enhancing the
response of cultured rat granulosa cells to FSH by increas-
ing cAMP [22]; inhibiting FSH-stimulated oestradiol pro-
duction by rat granulosa cells [23-25]; inhibiting the
primordial to primary follicle transition in newborn rats
[26]; inhibiting insulin-dependent granulosa cell mitosis
[27,28] and inhibiting apoptosis by large granulosa cells
in culture (granulosa cells isolated from immature rat ova-
ries were separated based on their size eg small or large),
which do not express PR [29]. It was puzzling that RU486,
a PR antagonist, inhibited the anti-apoptotic action of
progesterone, given the absence of receptors from granu-
losa cell. Consequently it has been proposed that some of
the actions of progesterone, notably the inhibition of
apoptosis and insulin-dependent mitosis, are mediated
by non-genomic mechanisms [30,31]. The identification
of a progesterone binding protein (60 kDa P4BP) within
ovarian and granulosa cell lysates [32] and progestin
membrane receptors in rat corpora lutea [33], a tissue that
Steroid biosynthesis by the ovary Figure 1
Steroid biosynthesis by the ovary. In the theca, under the 
influence of LH, cholesterol is converted to pregnenolone 
and metabolised through a series of substrates ending in 
androgen production. The two-cell, two-gonadotrophin 
model comes into play with androgens produced by the 
theca cells transported to the granulosa cells where they are 
aromatised to oestrogens.
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does not express detectable levels of nuclear progesterone
receptors, may facilitate the actions of progesterone.
At ovulation, the Graafian follicle ruptures releasing the
ovum. Thereafter, the follicle undergoes remodelling to
form a corpus luteum, which secretes progesterone. The
ovulatory process is progesterone dependent. Inhibitors
of progesterone synthesis, notably aminoglutethimide,
epostane and RU486, have been shown to block LH-
induced ovulation in vivo and in vitro in rats and mice [34-
37]. There is also the suggestion that progesterone is
involved in stimulating ovulation in the human [38].
Firstly, it has been shown that the rise in progesterone pre-
cedes that of gonadotrophins [39,40]. Secondly, in lutein-
ised unruptured follicle (LUF) syndrome, the
preovulatory rise in progesterone observed in normal
women is delayed and follicles fail to rupture although
they undergo luteinisation [41]. Thirdly, the administra-
tion of RU486 blocked the LH surge and ovulation [42].
In specific terms, progesterone has been shown to
enhance the production of proteolytic enzymes important
for the rupture of follicles at ovulation [43], either
directly, or by enhancing endometrial relaxin production
[44], which is thought to stimulate the release of proteases
by granulosa cells [45]. The expression of two metallopro-
teinases ADAMTS-1 and cathepsin-L, thought to be
required for ovulation, by granulosa cells of anovulatory
follicles of PR null mice, is inhibited indicating a depend-
ence on PR for normal expression [46].
The importance of PR in female reproduction is under-
scored by the infertility of PR null mice [47]. Despite his-
tologically normal ovaries, these mice fail to ovulate even
after exogenous stimulation with gonadotrophins, as
indicated by the presence of unruptured preovulatory fol-
licles in the ovary and an absence of oocytes in the oviduct
and uterine horns [47]. The granulosa cells of these preo-
vulatory follicles luteinise, suggesting that PR is not
required for corpus luteum formation [46]. However, this
observation conflicts with the credible report of Natraj
and Richards (1993) [17], that progesterone acting at least
in part via PR, is required for luteinisation (see earlier par-
agraph). The development of PR-A and PR-B knockouts
reveals that PR-A is necessary for ovulation whereas PR-B
is not [48,49]. Consequently, PR-A knockouts were infer-
tile, the result of a failure to ovulate, whereas PR-B knock-
outs were ovulatory and produced viable offspring. These
studies further highlight the capacity of PR-A and PR-B to
mediate different actions of progesterone [50].
Androgens
Androgens, primarily androstenedione and testosterone,
are produced by theca cells in response to LH (Figure 1).
Androgens act via receptors (AR) localised to granulosa
cells, stromal cells [51-53], human theca cells [54] and
more recently, to rat, pig and mouse oocytes [55-57].
Androgens predominantly target granulosa cells where
they initiate scenarios depending on the developmental
status of the follicle and species. AR expression is highest
in granulosa cells of: preantral and antral follicles of pri-
mate ovaries [58,59]; small preantral and early antral fol-
licles of rat ovaries [53,60]; small antral follicles of
porcine ovaries [61]; preantral to early antral follicles of
bovine ovaries [62] and secondary and dominant follicles
of human ovaries [54]. The expression of AR may be influ-
enced by oocyte secreted factors. Tetsuka and colleagues
[53] reported that a gradient of AR immunostaining
existed in large follicles of the rat ovary, with cumulus
cells and antral granulosa cells strongly expressing AR pro-
tein and peripheral layers expressing less [53].
In the early stages of folliculogenesis, androgens appear to
promote follicular growth. Administration of testosterone
to pregnant ewes and thus prenatal treatment of fetuses
with androgen, led to decreased numbers of primordial
follicles and enhanced numbers of follicles at other stages
of development, indicating that testosterone was enhanc-
ing follicular recruitment [63]. Since testosterone can be
aromatised to oestrogen at this stage of development, it is
difficult to determine whether this is a direct effect of tes-
tosterone or an indirect effect, by way of providing sub-
strate for aromatisation. In female rhesus monkeys
prenatally androgenised with testosterone, large polyfol-
licular ovaries that resemble polycystic ovaries found in
women with polycystic ovary syndrome (PCOS) develop
[64-66]. The diameter of mouse preantral follicles cul-
tured in vitro for four days with either testosterone, dihy-
drotestosterone, androstenedione,
dehydroepiandrosterone or dehydroepiandrosterone sul-
fate, expanded and the granulosa cells labelled strongly
with bromodeoxyuridine, an indicator of cellular prolifer-
ation [67]. An AR antagonist, but not an aromatase inhib-
The structure of nuclear hormone receptors Figure 2
The structure of nuclear hormone receptors. These recep-
tors are composed of 5 structure-function domains labelled 
A-F (Mangelsdorf et al., 1995) The N-terminal region con-
tains domains A/B, the DNA binding domain (DBD) contains 
domain C, the hinge region contains domain D and the ligand 
binding domain (LBD) at the C-terminal end contains 
domains E/F. Transactivation domains AF1 and AF2 are found 
in the N-terminal region and the LBD, respectively (White & 
Parker 1998).
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itor, inhibited the growth response, indicating that
oestrogen converted from the androgens in culture, was
not responsible for follicle growth. A direct stimulatory
effect of androgens on mouse antral follicle growth in
vitro, has also been demonstrated [68]. More recently,
dihydrotestosterone has been shown to enhance porcine
granulosa cell proliferation, by potentiating the effects of
factors, most likely GDF9, secreted by denuded oocytes in
vitro [69]. In primates treated short term with androgens,
increased numbers of preantral and small antral follicles
were present in the ovary and the theca had undergone
hypertrophy [70]. In pigs, numbers of preovulatory folli-
cles and corpora lutea were increased when treated with
testosterone or dihydrotestosterone during the follicular
phase [56,71,72]. During late preovulatory development,
AR decline in most mammals, the exception being
humans and androgens are metabolised as opposed to
exerting direct effects on folliculogenesis [73].
Apart from effects on growth, androgens have been shown
to enhance the follicle stimulating hormone (FSH)-medi-
ated differentiation of granulosa cells, as indicated by an
increase in progesterone and oestradiol production [74-
76] and to play roles in oocyte maturation. In vitro, testo-
sterone induced the maturation of mouse oocytes arrested
at meiosis, via a transcription independent mechanism
[57]. The addition of flutamide, an AR antagonist,
blocked the maturation. Stimulatory effects of dihydrotes-
tosterone on FSH receptor mRNA expression by preovula-
tory follicles of gilts [56] and testosterone on FSH receptor
mRNA expression by primate primary follicles [77], have
also been reported. These studies suggest that androgens
can facilitate the response of follicles to FSH. Components
of the ovarian IGF-I signalling system have been shown to
be regulated by androgens. IGF-I and IGF-I receptor
mRNAs have been shown to be enhanced by both testo-
sterone and dihydrotestosterone in primates [78,79]. The
broad localisation of the IGF-I and IGF-I receptor mRNA's
(granulosa cells, theca, oocytes and interstitial cells) sug-
gests wide ranging roles for androgen in ovarian function.
Androgens have also been shown to impede follicular
development, enhancing follicular atresia in immature
rats primed with PMSG [80,81] and in estrogen-treated
hypophysectomised immature rats [82]. A single injection
of dihydrotestosterone to cycling mice reduced the
number of large follicles by fifty percent [83] and left the
mice subfertile. Androgens are reported to inhibit FSH-
stimulated LH receptor expression by granulosa cells
[84,85] and to modulate granulosa cell apoptosis,
enhancing the process in the rat [86], but demonstrating
a negative correlation with androgen receptor suggestive
of reduced effects on granulosa cell apoptosis, in the rhe-
sus monkey [58].
In humans, hyperandrogenism is a classic symptom of
PCOS [Reviews: [87-89]]. Abnormal steroidogenesis by
the ovary is responsible for the androgen excess, which is
thought to impact on the level and distribution of adipos-
ity in PCOS patients and predispose them to insulin resist-
ance and anovulation [90]. It is thought that the theca
cells of PCOS ovaries are not responsive to downregula-
tion by gonadotrophins allowing for unchecked androgen
production [91]. The hypertrophy of theca, which occurs
in PCOS ovaries, exacerbates the problem. Evidence for
the role of androgens in anovulation comes from PCOS
patients treated with the antiandrogen, flutamide. After
six months treatment, ovulation was restored [92]. In
addition, when hormone therapy for ovulation induction
(clomiphene and follicle stimulating hormone regimen)
was supplemented with cyproterone acetate, an antian-
drogen, ovulation and pregnancy rates were highest [93].
These reports however, are counterbalanced by a study in
which the antiandrogen, nilutamide, did not stimulate
ovulation in anovulatory PCOS patients [94]. The cystic
nature of PCOS ovaries has been replicated in the imma-
ture rat with a view to determining why anovulation
occurs. Collagen degradation of the follicular wall at ovu-
lation is essential for oocyte release. The role of matrix
metalloproteinases (MMP), which degrade collagen and
lysyl oxidase (LOX), a cross-linker of collagen and elastin
normally involved in collagen repair or reconstruction,
were investigated in this dehydroepiandrosterone-
induced rat model of PCOS [95]. The study established
that in response to androgen, MMP2 activity was signifi-
cantly reduced whereas LOX activity was significantly
enhanced, indicating that collagen breakdown and folli-
cle rupture could potentially be inhibited, thus explaining
the cystogenesis that occurs in PCOS. Clearly, the mecha-
nisms that lead to anovulation in a sub group of PCOS
patients are complex and not fully understood. Recent cri-
teria defining PCOS indicate that the ovary should con-
tain 12 follicles or more, 2–9 mm in diameter, or ovarian
volume greater than 10 cm3 [96]. The premature develop-
ment of follicles in PCOS ovaries is thought to be due to
the elevated levels of androgen. Support for this hypothe-
sis comes from the primate study discussed earlier [70].
Follicle development is either arrested as in anovulatory
PCOS, the follicles remaining healthy and steroidogenic
[97], or tending toward atresia as in ovulatory PCOS [98].
Elevated levels of androgens are thought to activate cell
death pathways in preantral granulosa cells [87]. The low
levels of aromatase in atretic follicles foster the conversion
of androgens to dihydrotestosterone rather than to oestro-
gen, perpetuating the androgen excess [99,100]. Recent
studies by Maciel and colleagues [101] propose an alter-
native theory to androgen stimulated follicular growth;
that follicular growth is actually slowed in PCOS ovaries
causing primary follicles to 'stockpile' [101]. Significantly
more primary, secondary and Graafian follicles wereReproductive Biology and Endocrinology 2006, 4:16 http://www.rbej.com/content/4/1/16
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found in PCOS ovaries compared with normal ovaries,
although the greatest increase in follicle numbers was
observed in what was termed 'classic' primary follicles,
that is those follicles in which the oocyte is surrounded by
a single layer of fully cuboidal granulosa cells. No changes
in primordial follicle numbers or the numbers of atretic
follicles were seen in PCOS ovaries [101], adding weight
to the 'stockpiling' theory.
Despite the apparent roles for androgens in the ovary,
studies on the testicular feminised mouse (Tfm), which
lack functional androgen receptors, indicate that AR are
not essential for fertility [102]. The reproductive lifespan
of these mice however, was reduced due to accelerated
aging of the ovary and they were subfertile [102]. The
development of an androgen receptor conditional knock-
out has furthered studies on androgen action in the ovary.
Female AR knockout mice have longer oestrous cycles and
reduced fertility, evident in fewer litters and reduced num-
bers of pups. Their ovaries contain normal numbers of fol-
licles, although large antral follicles appeared to have
fewer granulosa cells and there were reduced numbers of
corpora lutea [103]. These observations are consistent
with studies in PMSG treated immature rats, where andro-
gen reduced ovulation rate by decreasing the number of
granulosa cells per follicle [81]. Superovulation induction
in these androgen receptor knockouts, led to the forma-
tion of abnormal cumulus-oocyte complexes [103].
One of the most important roles played by androgens in
the ovary is in the synthesis of oestrogen. Androgens serve
as substrates of P450 aromatase, which mediates the con-
version to oestrogens [[104], Reviews [73,105]].
Oestrogens
The capacity of follicles to make oestrogen is first apparent
in the late preantral stage when they possess all the com-
ponents of the 'two cell, two gonadotrophins' model.
Although aromatase activity is present in small antral fol-
licles, oestrogen production at this stage of development
is limited by an inability to produce androgen substrate
for aromatization to oestrogen [106]. Growth beyond the
small antral stage is therefore characterised by increased
aromatase activity and androgen synthesis, which culmi-
nates in follicular oestrogen production. The preovulatory
follicle has the highest intrafollicular levels of estradiol,
primarily due to the size of its granulosa cell population
and its capacity for androgen aromatisation [107,108].
Oestrogens signal via receptors (ER) of which there are
two forms, ERα and ERβ [109-113], with ERβ being the
predominant form in the ovary [114,115]. A number of
variant forms of ERβ have been identified in the human
[Review: [116]]. ERβ mRNAs lacking exon 5 and/or 6
[117] and ERβ2/cx, ERβ2, ERβ4 and ERβ5 [118,119]
mRNAs are all expressed by the ovary. The functional sig-
nificance of these forms however, is unclear. During post-
natal development, the mRNA expression of ERβ
increases in synergy with the proliferation of granulosa
cells in the rat ovary. ERα mRNA levels in contrast, remain
stable after its initial induction [115], indicative of a more
widespread expression profile as highlighted by protein
localisation studies in the ovary [120-122]. Recent studies
using isotype-selective, estrogen receptor agonists have
assessed the individual roles that ERα and ERβ play in
female reproduction [123]. Distinct roles for each recep-
tor were identified: ERα inhibited ovulation, most likely
via an effect on the hypothalamo-pituitary axis and uter-
ine growth; while ERβ stimulated follicular growth,
decreased atresia, induced the expression of specific genes
and enhanced the number of oocytes released following
ovulation induction.
Oestrogen has acknowledged local intrafollicular actions
[[124,125], Reviews: [126-128]]. Administration of oes-
trogen to hypophysectomised rats stimulates the prolifer-
ation of granulosa cells in small preantral follicles and
reduces atresia [129,130]. Subsequent administration of
FSH to these oestrogen-primed hypophysectomised rats
results in increased follicular growth and differentiation
and antrum formation [131]. It is interesting to note that
although oestrogen alone is a potent mitogen on rodent
granulosa cells in vivo, it is devoid of mitogenic activity in
vitro. This indicates that the in vitro culture systems are
incapable of maintaining the mitogenic responsiveness of
granulosa cells to oestrogen and/or other intrafollicular
growth factors, some of thecal origin, may be involved in
the mitogenic actions of oestrogen [132]. Studies of Bley
and colleagues (1997) [133] indicate that a combination
of oestrogen and FSH or androgen, perhaps aromatised in
vitro to oestrogen and FSH, can stimulate granulosa cell
proliferation in vitro and that this effect is further ampli-
fied by insulin or IGF-1 [133]. It is not clear what genes
oestrogen induces in granulosa cells, but cyclin D2 [134],
inhibin α and inhibin βB [135] are likely candidates.
Oestrogen is also responsible for facilitating the differen-
tiation of granulosa cells including the induction of recep-
tor systems for FSH, LH and prolactin and it can influence
post-receptor mechanisms. In conjunction with LH and
FSH, E2  stimulates cAMP accumulation [136] and
increases the number of cAMP binding sites in granulosa
cells [137]. There is now evidence that FSH can activate
the IGF-1/phosphatidylinositol 3-kinase (PI3K)/phos-
phatidylinositol-dependent kinase 1 (PDK1) pathway in
granulosa cells with serum and glucocorticoid-induced
kinase (Sgk) and protein kinase B (PKB) or Akt, kinases
being phosphorylated [138]. These effects can be mim-
icked by forskolin, cAMP and IGF-1 and can conceivably
be enhanced by oestrogen. Targets for PKB and SgkReproductive Biology and Endocrinology 2006, 4:16 http://www.rbej.com/content/4/1/16
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include members of the forkhead (FOX) family of tran-
scription factors of which forkhead homologue of rhab-
domysarcoma (FKHR) is a member. FKHR is expressed by
granulosa cells, its expression enhanced by FSH and oes-
trogen [138]. The role of FKHR in granulosa cells has yet
to be elucidated but it may be linked with proliferation
since cells expressing FKHR also expressed cyclin D2 and
showed enhanced staining for proliferating cell nuclear
antigen (PCNA) [139,140].
Oestrogen Receptor Knockout mice
In recent years, oestrogen receptor knockout mice have
been generated in an effort to define the points of oestro-
gen action in the ovary. The ERα knockout (ERKO) and
ERβ knockout (BERKO) mice however, are not oestrogen-
free given their capacity to transduce a signal via the alter-
native oestrogen receptor subtype. The female ERKOs are
acyclic, infertile and possess hyperemic ovaries devoid of
corpora lutea. Folliculogenesis is arrested at the antral
stage with large follicles becoming cystic and haemor-
rhagic [141,142]. Prolonged administration of a GnRH
antagonist to ERKO mice prevented formation of the
haemorrhagic cysts [143], indicating that the ovarian phe-
notype manifests as a consequence of elevated LH levels
[144,145]. Gonadotrophin-treated prepubescent ERKO
mice ovulate, although they released fewer oocytes com-
pared to their wildtype counterparts [146]. Thus, it would
appear that folliculogenesis, ovulation and corpora lutea
formation can occur in the absence of ERα, albeit subop-
timally.
The female BERKOs [147-149] have small ovaries, par-
tially arrested follicular development associated with
increased numbers of primordial follicles, but signifi-
cantly fewer numbers of primary and large antral follicles
and corpora lutea. Increased atresia of large follicles is evi-
dent. In culture, BERKO follicle growth was retarded and
they produced significantly less oestrogen and expressed
less aromatase than wildtype follicles [149]. Compro-
mised fertility was evident in reduced numbers of off-
spring/litter, consistent with the reduced numbers of
corpora lutea [147]. Following ovulation induction, fewer
oocytes were released from BERKO ovaries relative to their
wildtype counterparts. This is likely to be due to reduced
Ptgs2 expression, a gene necessary for ovulation, by
BERKO follicles after gonadotrophin stimulation
[149,150]. Interestingly, gonadotrophin levels in these
mice are normal. These studies indicate that ERβ plays an
essential role in gonadotrophin-induced granulosa cell
differentiation. In its absence, follicle maturation and the
ovulatory process are impaired. Androgen receptor (AR)
analyses of BERKO mice ovaries revealed an increased
expression of AR in late antral and atretic follicles [148], a
time in wildtype animals when AR expression is low.
Androgens are known to enhance atresia [80-82] and thus
the overexpression of AR by the ovaries of BERKO mice
most likely accounts for the increased atresia and prema-
ture exhaustion of follicles observed in these mice. Treat-
ment with the antiandrogen, flutamide reversed the
BERKO ovarian phenotype, the ovaries containing
healthy late antral follicles and increased numbers of cor-
pora lutea [148]. A role for androgens in the manifesta-
tion of the BERKO phenotype and thus in ovarian
folliculogenesis is clearly indicated.
The generation of double ER knockout (αβERKO) mice by
two laboratories [151,152] and reports of their ovarian
phenotype, indicate that these mice are distinct from the
individual ER knockouts. These ovaries exhibit follicular
trans/re-differentiation with tubular-like structures con-
taining Sertoli-like cells. Where oocytes were present these
were seen to be degenerating, raising the possibility that
factors produced by the oocyte may be involved in the
transformation process. The capacity to be effected by oes-
trogens or a lack there of, is asserted by the presence of
ERα mRNA in mouse and human oocytes [153-155]. The
phenotype is expressed in the presence of elevated LH lev-
els, similar to that of the ERKO mouse. Thus it appears
that both ERs have roles to play in the maintenance of fer-
tility, although ERβ appears essential for follicle develop-
ment and maturation.
Oestrogen depletion – the ArKO mouse
An alternative model to ER depletion is to remove oestro-
gen itself from the ovary. Targeted deletion of most of
exon 9 of the Cyp 19 (aromatase) gene has given rise to a
mouse which lacks functional aromatase and thus an ina-
bility to produce oestrogen [156]. Female ArKO mice have
undetectable levels of aromatase and oestrogens but
exhibit high levels of testosterone, FSH and LH in serum.
These reproductive hormones have been implicated as
playing crucial roles in various aspects of folliculogenesis
[Reviews: [157,158]]. The ArKO model has allowed us to
define how far follicles can grow in the total absence of
oestrogen [156,159,160]. We established that follicle
development was arrested at the antral stage rendering
these mice infertile due to an inability to ovulate. The
antral follicles that were present appeared morphologi-
cally atretic or prematurely luteinized, as evidenced by the
presence of pyknotic nuclei or cytoplasmic lipid droplets,
respectively. The phenotype exacerbates with age, the
ovarian interstitium becoming increasingly diffuse and
containing increasing numbers of morphologically
abnormal follicles and haemorraghic cysts [160]. Second-
ary and antral follicles become less common in the ovary
and eventually the number of primary follicles also
decreases [159,161]. Recent studies quantitating the pri-
mordial follicle pool, indicate that there are reduced num-
bers of primordial follicles in ArKO ovaries and that their
oocytes are enlarged [162].Reproductive Biology and Endocrinology 2006, 4:16 http://www.rbej.com/content/4/1/16
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The phenotype of the somatic cells in the ArKO ovary, has
been investigated both ultrastructurally and immunohis-
tochemically [160,161] and gene expression studies have
been performed [163]. Detailed light microscopy identi-
fied the abnormal follicles as seminiferous tubule-like
structures filled with Sertoli-like somatic cells, apparently
arising from the trans/re-differentiation of granulosa cells.
These Sertoli-like cells possess adult-type Sertoli cells char-
acteristics, including a tall irregular columnar shape and
lateral cylindrical-like processes; basally located nuclei;
prominent tripartite nucleoli and a homogeneous nuclear
chromatin distribution, specialised desmosome-like
adherens junctions and Sertoli-cell specific, ectoplasmic
specialisations between cells [160]. Cells morphologically
resembling testicular Leydig cells were present within the
interstitial regions of ArKO ovaries [160,164]. These Ley-
dig cell-like cells contain an abundance of smooth endo-
plasmic reticulum, often present in whorl-like formations
and the nucleus accommodated an annular nucleolus, all
characteristics of murine Leydig cells. It is unclear at this
stage if these cells are functional ie., whether they possess
steroidogenic enzymes. The expression of the male type
genes, Sox 9 and Mullerian inhibiting substance (MIS)
were increased in ArKO mice ovaries [163], indicating that
oestrogen is required for maintenance of the female phe-
notype of ovarian somatic cells. Thus, in the absence of
oestrogen, the ovaries undergo sex reversal and testicular
type cells appear, indicating that gonadal cells retain a
degree of plasticity. Oestrogen replacement partially
restored the ovarian phenotype, eliminating male-like
cells from the ovary and allowing limited ovulation in
some ArKO mice [162,163].
These data confirm and extend observations in αβERKO
mice in which Sertoli-like cells with similar properties
were observed in the ovaries [151,152]. These compound
ER knockouts are not oestrogen-free and it is possible that
there remains an influence of oestrogen via some as-yet
unidentified ER, particularly since an ERγ form has been
identified in fish [165]. A non-genomic action of oestro-
gen can also not be ruled out. The presence of Sertoli-like
and Leydig-like cells in the ovaries of ArKO mice on a phy-
toestrogen-free diet, indicates that these cells only develop
in the complete absence of oestrogen. Thus oestrogen is
required for normal folliculogenesis, from the antral stage
on. The development of antral and preovulatory follicles
is prerequisite for ovulation and corpus luteum formation
and for the maintenance of fertility.
The role of the oocyte in the trans/redifferentiation of
granulosa cells in these animal models has been unclear.
Recent studies in irradiated rats [166] have addressed this
question. Oocytes in non-growing follicles were selec-
tively destroyed by gamma irradiation. The follicular cells
that remained differentiated into Sertoli-like cells and
expressed morphological characteristics of Sertoli cells,
although some traits of follicular cells, such as the expres-
sion of FOXL2 protein remained. These cells did not
express oestrogen receptors, so despite normal levels of
oestrogen, a signal could not be transduced by them.
Despite similarities with the sex reversed cells reported in
ArKO or ER double knockout mouse ovaries, these
transdifferentiated follicular cells did not express Sox 9.
They also established a role for FSH in the development of
these transdifferentiated oocyte depleted follicles. While
FSH levels are elevated in ArKO mice [159], a role for FSH
in the development of sex-reversed cells has yet to be
shown. Studies to elucidate the oestrogen-mediated
mechanisms that operate between the oocyte and the
somatic cells, to maintain and promote the follicular-
granulosa cell phenotype are only just starting to be
undertaken. Otsuka and colleagues [167] recently
reported that oocytes mediate oestrogen's enhancement
of FSH action on P450 aromatase, FSH and LH receptor
and inhibin/activin subunit mRNA expression and cAMP
production by granulosa cells in vitro [167].
Conclusion
Steroid hormones, via ligand-specific receptors, play
important regulatory roles in the ovary. The impact of
these hormones on ovarian function is determined by lig-
and availability, receptor expression and the repression or
induction of relevant regulatory genes. Ultimately, it is the
needs of individual follicle populations, which determine
the roles that steroids play. From the data presented in this
review, it is clear that each steroid plays roles of conse-
quence for fertility. In their absence, or in cases of excess,
ovarian function and subsequently fertility, is compro-
mised.
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